NasdaqGS:HALOBiotechs
Halozyme Therapeutics (HALO): A Fresh Look at Valuation After Board Appointment of Dealmaker Jim Lang
Halozyme Therapeutics (HALO) just added seasoned healthcare dealmaker Jim Lang to its board, and that move has investors asking whether fresh strategic eyes could help unlock more value after a mixed few months for the stock.
See our latest analysis for Halozyme Therapeutics.
The timing is interesting, as Halozyme’s share price sits at 63.45 dollars after a solid year to date share price return of just over 32 percent. However, the 3 year total shareholder return is a more modest 12 percent,...